Thursday, February 25, 2010
For many years, cancer patients have been treated with radioactive substances in hopes of shrinking their cancer and extending their lives. Now nuclear medicine specialists at the Albert Einstein College of Medicine are studying radioactive antibodies and their ability to kill HIV. So far the results have been favorable. In their studies using HIV-infected mice, researchers attached two radioactive isotopes to the antibodies that normally attach to proteins found on the surface of HIV-infected cells.
By attaching only to HIV infected cells, the lethal radiation killed the infected cells while leaving the healthy, functioning CD4 cells unharmed. By killing infected cells, HIV replication is slowed or halted, which in turn may slow the progression from HIV to AIDS. In the case of this study, researchers are now looking for a pharmaceutical sponsor that is interested in taking trials to the next step - developing an FDA-approved therapy against HIV.
By targeting therapy to the most highly infectious it seems possible to significantly reduce the rate of new infections in others, but also in larger population's potentially whole nations where a common HIV strain is dominant.
posted by emedinfo
@10:13 PM
permanent link |
|
| Bookmark & Share |
|
|
<< Home